Literature DB >> 15596187

Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years.

Bob Djavan1, Yan Kit Fong, Mike Harik, Shirin Milani, Andreas Reissigl, Aziz Chaudry, Theodore Anagnostou, Fariborz Bagheri, Matthias Waldert, Soren Kreuzer, Harun Fajkovic, Michael Marberger.   

Abstract

OBJECTIVES: To determine the risk of clinical progressions in men with mild lower urinary tract symptoms of bladder outlet obstruction and identify the predictors for progression in this group of men.
METHODS: A total of 397 men who presented to the urology clinics with mild symptoms of bladder outlet obstruction (International Prostate Symptom Score less than 8) were analyzed in this longitudinal study conducted during a 4-year period. They began with the watchful waiting protocol and were followed up every 3 months for 48 months. Age, International Prostate Symptom Score (IPSS), divided into obstructive symptom score and irritative symptom score, serum prostate-specific antigen level, total prostate volume, transitional zone volume, urinary flow rates, and postvoid residual urine volume were documented.
RESULTS: The cumulative incidence of clinical progression, defined as worsening of the IPSS with migration to the moderate symptom group (IPSS 8 to 18) or severe symptom group (IPSS 19 to 35) and an increase in IPSS of more than 2 points, was 6%, 13%, 15%, 24%, 28%, and 31% at 6, 12, 18, 24, 36, and 48 months, respectively. Nineteen patients (4.9%) developed acute urinary retention within the 48-month follow-up period. Of these 19 patients, only 2 (0.6%) required transurethral resection of the prostate. The variables of importance for disease progression in the artificial neural network analysis were, in order of statistical significance, prostate-specific antigen level, obstructive symptom score, and transitional zone volume.
CONCLUSIONS: The risk for men with mild symptoms of bladder outlet obstruction to progress clinically and develop complications such as acute retention of urine is moderate. Prostate-specific antigen, obstructive symptom score, and transitional zone volume were identified as important risk factors.

Entities:  

Mesh:

Year:  2004        PMID: 15596187     DOI: 10.1016/j.urology.2004.08.049

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  18 in total

1.  2010 Update: Guidelines for the management of benign prostatic hyperplasia.

Authors:  J Curtis Nickel; Carlos E Méndez-Probst; Thomas F Whelan; Ryan F Paterson; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

Review 2.  Acute urinary retention: who is at risk and how best to manage it?

Authors:  Anand Patel; Christopher Chapple
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 3.  The evaluation and treatment of prostate-related LUTS in the primary care setting: the next STEP.

Authors:  Matt T Rosenberg; David Staskin; John Riley; Grannum Sant; Martin Miner
Journal:  Curr Urol Rep       Date:  2013-12       Impact factor: 3.092

Review 4.  Use of 5alpha-reductase inhibitors to prevent benign prostatic hyperplasia disease.

Authors:  Leonard S Marks
Journal:  Curr Urol Rep       Date:  2006-07       Impact factor: 3.092

Review 5.  Best practice in the management of storage symptoms in male lower urinary tract symptoms: a review of the evidence base.

Authors:  Mauro Gacci; Arcangelo Sebastianelli; Pietro Spatafora; Giovanni Corona; Sergio Serni; Dirk De Ridder; Stavros Gravas; Paul Abrams
Journal:  Ther Adv Urol       Date:  2017-12-07

6.  Assessment of noninvasive predictors of bladder detrusor underactivity in BPH/LUTs patients.

Authors:  Fei Luo; Hong-Hong Sun; Yan-Hui Su; Zhi-Hua Zhang; Ya-Shen Wang; Zhen Zhao; Jian Li
Journal:  Int Urol Nephrol       Date:  2017-02-15       Impact factor: 2.370

7.  The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment.

Authors:  Young Kee Kwon; Mi Sun Choe; Kyung Won Seo; Chol Hee Park; Hyuk Soo Chang; Byung Hoon Kim; Chun Il Kim
Journal:  Korean J Urol       Date:  2010-04-20

8.  Prospective factor analysis of alpha blocker monotherapy failure in benign prostatic hyperplasia.

Authors:  Kyoung Pyo Hong; Young Joon Byun; Hana Yoon; Young Yo Park; Woo Sik Chung
Journal:  Korean J Urol       Date:  2010-07-20

Review 9.  Primary care physician versus urologist: how does their medical management of LUTS associated with BPH differ?

Authors:  Martin M Miner
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

10.  A-blockers for the management of lower urinary tract symptoms in patients with prostate cancer treated with external beam radiotherapy: a randomized controlled study.

Authors:  Kimon Tsirkas; Anna Zygogianni; Andromachi Kougioumtzopoulou; Vasileios Kouloulias; Zoi Liakouli; Athanasios Papatsoris; John Georgakopoulos; Christos Antypas; Christina Armpillia; Athanasios Dellis
Journal:  World J Urol       Date:  2020-08-10       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.